Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS: Switching to Long-acting Cabotegravir Plus Rilpivirine in Virologically Suppressed HIV-1-infected Adults
NCT02951052Phase 3Active, not recruiting
- Sponsor
- ViiV Healthcare
- Start
- Oct 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of cabotegravir, rilpivirine in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Started Oct 2016; status: active, not recruiting.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02951052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02951052.